All In Biotech

Drug Trial Radar · NCT02496221

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

A Randomized, Double-blind, Single-dose, Placebo Controlled, 2-way Cross-over Study Evaluating Effect of Albiglutide on Cholecystokinin-induced Gallbladder Emptying in Fasting Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Jun 11, 2015

Primary completion

Oct 13, 2015

Study completion Oct 13, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 14, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Albiglutide, a novel analogue of glucagon-like peptide-1 (GLP-1), has been developed and approved for the treatment of type 2 diabetes mellitus. The primary objective of this study is to assess if a single dose of albiglutide can affect cholecystokinin-induced gallbladder emptying. To make this assessment, each study participant will receive a dose of albiglutide and a dose of placebo followed by cholecystokinin (CCK) infusion and ultrasound measurement of the gallbladder. The study will be comprised of two periods and 20 subjects. The screening visit will occur within 42 days of the start of Treatment Period 1. The Treatment Periods will be separated by a washout period of a minimum of 42 days. Subjects will return for a follow-up visit after 28 days following the last dose of albiglutide or placebo. The total duration of a subject's participation from Screening to Follow-up will be approximately 17.5 weeks. This study is a post marketing commitment to the United States Food and Drug Administration (USFDA).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Albiglutide 50 mgDrug

    Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution

  • PlaceboDrug

    Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen

  • CCK (Kinevac)Drug

    CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Absolute Value of Gallbladder Ejection Fraction (Emax GEF) During Cholecystokinin (CCK) Infusion, as a Measure of Maximum EffectTime frame: Day 4 in each treatment period
  2. Area Under the Effect Curve for Gallbladder Ejection Fraction (AUEC GEF)Time frame: Day 4 in each treatment period
  3. Time at Which the Maximum Effect (Emax GEF) Occurred (TEMAXEF) During the CCK InfusionTime frame: Day 4 in each treatment period
  4. Maximum Gallbladder Ejection Fraction Value During CCK InfusionTime frame: Day 1 and Day 4 in each treatment period
  5. Area Under the Effect Curve for Gallbladder Volume (AUEC VL)Time frame: Day 4 in each treatment period
  6. Maximum Absolute Change From Baseline in Value of Gallbladder Volume (Emax VL) During CCK Infusion, as a Measure of Maximum EffectTime frame: Day 4 in each treatment period
  7. Time at Which the Maximum Effect (Emax VL) Occurred (TEmax VL) During the CCK InfusionTime frame: Day 4 in each treatment period
  8. Maximum Change From Baseline in Main Pancreatic Duct Diameter During CCK InfusionTime frame: Day 4 in each treatment period
  9. Maximum Change From Baseline in Common Bile Duct Diameter During CCK InfusionTime frame: Day 4 in each treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.